

Mandeep Bajaj

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1083232/publications.pdf>

Version: 2024-02-01

31
papers

1,862
citations

331259

21
h-index

454577

30
g-index

31
all docs

31
docs citations

31
times ranked

2642
citing authors

#	ARTICLE	IF	CITATIONS
1	SGLT2 Inhibition by Dapagliflozin Attenuates Diabetic Ketoacidosis in Mice with Type-1 Diabetes. <i>Cardiovascular Drugs and Therapy</i> , 2022, 36, 1091-1108.	1.3	2
2	Metastatic Insulinoma Presenting With Post-Prandial Hypoglycemia. <i>Journal of the Endocrine Society</i> , 2021, 5, A999-A1000.	0.1	0
3	Acupuncture Reduces Hypertrophy and Cardiac Fibrosis, and Improves Heart Function in Mice with Diabetic Cardiomyopathy. <i>Cardiovascular Drugs and Therapy</i> , 2020, 34, 835-848.	1.3	13
4	miR-30a targets gene networks that promote browning of human and mouse adipocytes. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 2020, 319, E667-E677.	1.8	14
5	Diabetes and covid-19: a global health challenge. <i>BMJ Open Diabetes Research and Care</i> , 2020, 8, e001450.	1.2	38
6	DPP-4 inhibition by linagliptin prevents cardiac dysfunction and inflammation by targeting the Nlrp3/ASC inflammasome. <i>Basic Research in Cardiology</i> , 2019, 114, 35.	2.5	49
7	Combined SGLT2 and DPP4 Inhibition Reduces the Activation of the Nlrp3/ASC Inflammasome and Attenuates the Development of Diabetic Nephropathy in Mice with Type 2 Diabetes. <i>Cardiovascular Drugs and Therapy</i> , 2018, 32, 135-145.	1.3	89
8	GLP-1 Receptor Agonists and Cardiovascular Disease: a Meta-Analysis of Recent Cardiac Outcome Trials. <i>Cardiovascular Drugs and Therapy</i> , 2018, 32, 65-72.	1.3	27
9	Evaluation of a Mixed Meal Test for Diagnosis and Characterization of Pancreatic Diabetes Secondary to Pancreatic Cancer and Chronic Pancreatitis. <i>Pancreas</i> , 2018, 47, 1239-1243.	0.5	32
10	Dapagliflozin Attenuates Na ⁺ /H ⁺ Exchanger-1 in Cardiofibroblasts via AMPK Activation. <i>Cardiovascular Drugs and Therapy</i> , 2018, 32, 553-558.	1.3	73
11	miR-30a Remodels Subcutaneous Adipose Tissue Inflammation to Improve Insulin Sensitivity in Obesity. <i>Diabetes</i> , 2018, 67, 2541-2553.	0.3	60
12	SGLT2 Inhibitors and Cardiovascular Outcomes: Current Perspectives and Future Potentials. <i>Current Diabetes Reports</i> , 2018, 18, 63.	1.7	12
13	SGLT-2 Inhibition with Dapagliflozin Reduces the Activation of the Nlrp3/ASC Inflammasome and Attenuates the Development of Diabetic Cardiomyopathy in Mice with Type 2 Diabetes. Further Augmentation of the Effects with Saxagliptin, a DPP4 Inhibitor. <i>Cardiovascular Drugs and Therapy</i> , 2017, 31, 119-132.	1.3	281
14	Alelitazar, a dual peroxisome proliferator-activated receptor- α and - β agonist, protects cardiomyocytes against the adverse effects of hyperglycaemia. <i>Diabetes and Vascular Disease Research</i> , 2017, 14, 152-162.	0.9	8
15	Type 2 diabetes and cardiovascular disease: A metabolic overview of recent clinical trials. <i>Journal of Diabetes and Its Complications</i> , 2017, 31, 291-294.	1.2	3
16	Adiponectin is required for maintaining normal body temperature in a cold environment. <i>BMC Physiology</i> , 2017, 17, 8.	3.6	38
17	Alelitazar, a Balanced Dual PPAR α and - β Agonist, Protects the Heart Against Ischemia-Reperfusion Injury. <i>Cardiovascular Drugs and Therapy</i> , 2016, 30, 129-141.	1.3	11
18	Dipeptidyl peptidase-4 inhibition by Saxagliptin prevents inflammation and renal injury by targeting the Nlrp3/ASC inflammasome. <i>BMJ Open Diabetes Research and Care</i> , 2016, 4, e000227.	1.2	64

#	ARTICLE	IF	CITATIONS
19	Ubc9 Impairs Activation of the Brown Fat Energy Metabolism Program in Human White Adipocytes. <i>Molecular Endocrinology</i> , 2015, 29, 1320-1333.	3.7	10
20	PTEN Upregulation May Explain the Development of Insulin Resistance and Type 2 Diabetes with High Dose Statins. <i>Cardiovascular Drugs and Therapy</i> , 2014, 28, 447-457.	1.3	25
21	The regulation of muscle protein turnover in diabetes. <i>International Journal of Biochemistry and Cell Biology</i> , 2013, 45, 2239-2244.	1.2	36
22	Phosphodiesterase-3 inhibition augments the myocardial infarct size-limiting effects of exenatide in mice with type 2 diabetes. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2013, 304, H131-H141.	1.5	21
23	Myocardial Protection Against Ischemia-Reperfusion Injury by GLP-1: Molecular Mechanisms. <i>Metabolic Syndrome and Related Disorders</i> , 2012, 10, 387-390.	0.5	14
24	Nicotine and Insulin Resistance: When the Smoke Clears. <i>Diabetes</i> , 2012, 61, 3078-3080.	0.3	54
25	Phosphodiesterase III Inhibition Increases cAMP Levels and Augments the Infarct Size Limiting Effect of a DPP-4 Inhibitor in Mice with Type-2 Diabetes Mellitus. <i>Cardiovascular Drugs and Therapy</i> , 2012, 26, 445-456.	1.3	25
26	Decreased Plasma Adiponectin Concentrations Are Closely Related to Hepatic Fat Content and Hepatic Insulin Resistance in Pioglitazone-Treated Type 2 Diabetic Patients. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2004, 89, 200-206.	1.8	340
27	Sustained Reduction in Plasma Free Fatty Acid Concentration Improves Insulin Action without Altering Plasma Adipocytokine Levels in Subjects with Strong Family History of Type 2 Diabetes. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2004, 89, 4649-4655.	1.8	96
28	Metabolic and molecular basis of insulin resistance. <i>Journal of Nuclear Cardiology</i> , 2003, 10, 311-323.	1.4	96
29	Pioglitazone Reduces Hepatic Fat Content and Augments Splanchnic Glucose Uptake in Patients With Type 2 Diabetes. <i>Diabetes</i> , 2003, 52, 1364-1370.	0.3	265
30	Free Fatty Acids Reduce Splanchnic and Peripheral Glucose Uptake in Patients With Type 2 Diabetes. <i>Diabetes</i> , 2002, 51, 3043-3048.	0.3	44
31	Free fatty acid-induced peripheral insulin resistance augments splanchnic glucose uptake in healthy humans. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 2002, 283, E346-E352.	1.8	22